ANG1005 for breast cancer brain metastases: correlation between ¹⁸F-FLT-PET after first cycle and MRI in response assessment.

ABSTRACT:

Purpose

Improved therapies and imaging modalities are needed for the treatment of breast cancer brain metastases (BCBM). ANG1005 is a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, designed to cross the blood-brain barrier. We conducted a biomarker substudy to evaluate ¹⁸F-FLT-PET for response assessment.

Methods

Ten patients with measurable BCBM received ANG1005 at a dose of 550 mg/m² IV every 21 days. Before and after cycle 1, patients underwent PET imaging with ¹⁸F-FLT, a thymidine analog, retention of which reflects cellular proliferation, for comparison with gadolinium-contrast magnetic resonance imaging (Gd-MRI) in brain metastases detection and response assessment. A 20 % change in uptake after one cycle of AN

SUBMITTER: O'Sullivan CC 

PROVIDER: S-EPMC6362453 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature